Lucosky Brookman’s client NeurAxis, Inc. (AMEX: NRXS), a pioneering medical technology company specializing in the development of innovative neuromodulation therapies aimed at addressing chronic and debilitating conditions in both children and adults, has successfully priced its underwritten initial public offering. Lucosky Brookman is pleased to represent NeurAxis in this pivotal moment.
